07:00 , Sep 19, 2011 |  BioCentury  |  Emerging Company Profile

Galera: Replacing SOD

Galera: Replacing SOD...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Company News

AvtivBiotics Pharma, TrioBiotics Pharma AG deal

The companies mutually terminated TrioBiotics' proposed acquisition of ActivBiotics. ActivBiotics said the termination was due to TrioBiotics' failure to raise €5 million ($6.6 million) to fund development of ActivBiotics' antibiotic rifalazil . In July, TrioBiotics...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Prolong Pharmaceuticals management update

Prolong Pharmaceuticals LLC , South Plainfield, N.J.   Business: Cardiovascular, Hematology   Hired: Glenn Kazo as president, formerly CBO of ActivBiotics Inc. ; he replaces Abraham Abuchowski, who remains CEO  ...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

Questions of the heart

On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

ActivBiotics infectious news

ActivBiotics completed the sale of its IP covering rifalazil , antibacterial NCEs and superoxide dismutase small molecule mimetics to an undisclosed buyer for $3.5 million. The company sold its fixed assets to an undisclosed buyer...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Clinical News

M40403 regulatory update

FDA granted Orphan Drug designation for M40403 to prevent oral mucositis in cancer patients receiving radiation or chemotherapy. The superoxide dismutase (SOD), which already has Orphan Drug designation in Europe for the indication, has completed...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

Cubist management update

Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass.   Business: Infectious   Hired: Steven Gilman as CSO and SVP of discovery and non-clinical development, formerly chairman and CEO of ActivBiotics Inc.  ...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Clinical News

M40403 regulatory update

EMEA's COMP granted Orphan Drug designation for M40403 to prevent oral mucositis in head and neck cancer patients receiving radiotherapy. ActivBiotics has completed Phase I testing with the superoxide dismutase (SOD). ActivBiotics Inc. , Lexington,...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Company News

ActivBiotics infectious news

ActivBiotics completed the sale of its fixed assets to an undisclosed buyer for about $300,000 in a Jan. 24 auction. Another auction will begin on March 14 for the company’s IP covering rifalazil , antibacterial...